What is Immunovant, Inc.'s cumulative milestone payments?

Immunovant, Inc. (IMVT) reported cumulative milestone payments of $32.5M in Q4 2025.

How has Immunovant, Inc.'s cumulative milestone payments changed year-over-year?

Immunovant, Inc.'s cumulative milestone payments decreased by 0.0% year-over-year, from $32.5M to $32.5M.

Net income-$147.9M-38.9%

EPS (diluted)-$0.73-15.9%

Cash & equivalents$902.1M+26.4%

Total debt$72.0K-26.5%

Total equity$852.6M+20.5%

Total assets$957.0M+23.3%

Operating cash flow-$95.1M+14.1%

CapEx$8.0K-96.0%

Free cash flow-$95.1M+14.2%

Market cap$7.26B+74.2%

Enterprise value$6.35B+89.7%

Return on equity-64.8%+2.5pp

Debt / equity0×0.0×

Current ratio9.1×-2.1×

Reported directly by Immunovant, Inc. in its filing.

Tagged under the XBRL concept imvt:CumulativeMilestonePayments.

The official record: Immunovant, Inc.’s 10-Q, filed February 6, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and see it in context, right in your chat.

What is Immunovant, Inc.'s cumulative milestone payments?: Immunovant, Inc. (IMVT) reported cumulative milestone payments of $32.5M in Q4 2025.
How has Immunovant, Inc.'s cumulative milestone payments changed year-over-year?: Immunovant, Inc.'s cumulative milestone payments decreased by 0.0% year-over-year, from $32.5M to $32.5M.